IOP DRUG UNDER REVIEW

IOP DRUG UNDER REVIEW

Colin Kerr

Published: Thursday, November 1, 2018

Pharmaceuticals has reported that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%. Rhokiinsa is currently marketed as Rhopressa® in the United States and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. An opinion from the EMA’s Committee for Medicinal Products for Human Use on the MAA for Rhokiinsa is expected in the second half of 2019. “We are delighted that the European regulatory authorities have accepted our Rhokiinsa filing for review. If Rhokiinsa is approved, we plan to submit an MAA for Roclatan™ shortly thereafter,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie. www.aeriepharma.com

Tags: glaucoma, intraocular pressure

Latest Articles

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

New Award to Encourage Research into Sustainable Practices

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

AI Scribing and Telephone Management

Automating note-taking and call centres could boost practice efficiency.

AI Analysis and the Cornea

A combination of better imaging and AI deep learning could significantly improve corneal imaging and diagnosis.

Cooking a Feast for the Eyes

A cookbook to promote ocular health through thoughtful and traditional cuisine.

Need to Know: Spherical Aberration

Part three of this series examines spherical aberration and its influence on higher-order aberrations.

Generating AI’s Potential

How generative AI impacts medicine, society, and the environment.